2seventy bio plucks Turnstone Biologics exec Bernstein to be new CMOnews2022-02-14T15:27:47+00:00February 14th, 2022|FierceBiotech|
Kallyope, with ex-Merck exec at helm, skirts ‘less desirable’ public markets with $236M series Dnews2022-02-14T15:25:41+00:00February 14th, 2022|FierceBiotech|
Improving RNA editing for genetic diseases by recruiting the body’s natural proteinnews2022-02-14T14:51:55+00:00February 14th, 2022|FierceBiotech|
Roivant decants another Vant armed with Eisai blood cancer drug and plans to start phase 1/2 soonnews2022-02-14T13:35:51+00:00February 14th, 2022|FierceBiotech|
FDA fingers tox assessment as cause of Denali clinical hold, leaving biotech with a to-do list to regain momentumnews2022-02-14T12:51:38+00:00February 14th, 2022|FierceBiotech|
Editor’s Corner: Fierce Biotech gets a fierce makeovernews2022-02-11T20:14:26+00:00February 11th, 2022|FierceBiotech|
Roche, Lilly push back against CMS painting their Alzheimer’s meds with the same brush as Biogen’s Aduhelmnews2022-02-11T17:40:09+00:00February 11th, 2022|FierceBiotech|
ProQR shares plummet as eye disease treatment flops phase 2/3 pediatric trialnews2022-02-11T15:47:10+00:00February 11th, 2022|FierceBiotech|
Ex-FDA interim chief Giroir rejoins biotech world with eyes on $50M fundraising for new infectious disease companynews2022-02-11T14:57:49+00:00February 11th, 2022|FierceBiotech|
Cassava scores a win as FDA declines to intervene in petition to stop its Alzheimer’s drug trialsnews2022-02-11T14:36:55+00:00February 11th, 2022|FierceBiotech|
